48. two. Elias AD: Triple-negative breast cancer. Am J Clin Oncol 2010, 33:637?45. 3. Carey LA

48. 2. Elias AD: Triple-negative breast cancer. Am J Clin Oncol 2010, 33:637?45. 3. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MCU, Nielsen TO, Moorman PG, Earp HS, Millikan RC: Race, breast cancer subtypes, and survival inside the Carolina breast cancer study. JAMA 2006, 295:2492?502. four. Weigelt B, Baehner FL, Reis-Filho JS: The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective with the final decade. J Pathol 2010, 220:263?80. 5. Banerjee S, Dowsett M, Ashworth A, Martin LA: Mechanisms of disease: angiogenesis along with the management of breast cancer. Nat Clin Pract Oncol 2007, four(9):536?50. 6. Pal SK, Figlin RA, Yu H: Deciphering the anticancer mechanisms of sunitinib. Cancer Biol Ther 2010, ten:712?14. 7. Paulsson J, Sj lom T, Micke P, Pont F, Landberg G, Heldin CH, Bergh J, Brennan DJ, Jirstr K, Ostman A: Prognostic significance of stromal platelet-derived growth element beta-receptor expression in human breast cancer. Am J Pathol 2009, 175:334?41. eight. Goswami S, Sahai E, Wyckoff JB, Cammer M, Cox D, Pixley FJ, Stanley ER, Segall JE, Condeelis JS: Macrophages promote the invasion of breast carcinoma cells by means of a colony-stimulating factor-1/epidermal growth issue paracrine loop. Cancer Res 2005, 65:5278?283. 9. Charpin C, Giusiano S, Charfi S, Secq V, Carpentier S, Andrac L, Lavaut MN, Allasia C, Bonnier P, Garcia S: Quantitative immunohistochemical expression of c Kit in breast carcinomas is predictive of patients’ outcome. Br J Cancer 2009, 101:48?4. ten. Tsuda H, Tani Y, Weisenberger J, Kitada S, Hasegawa T, Murata T, Tamai S, Hirohashi S, Matsubara O, Natori T: Frequent KIT and epidermal growth aspect receptor overexpressions in undifferentiated-type breast carcinomas with `stem-cell-like’ functions.Price of 1141886-37-4 Cancer Sci 2005, 96:333?39.H-Glu-OtBu site 11.PMID:33736562 Young E, Miele L, Tucker KB, Huang M, Wells J, Gu JW: SU11248, a selective tyrosine kinases inhibitor suppresses breast tumor angiogenesis and growth by way of targeting both tumor vasculature and breast cancer cells. Cancer Biol Ther 2010, 10:703?11. 12. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, HernandezBoussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM, Gilks CB, van de Rijn M, Perou CM: Immunohistochemical and clinical13.14.15.16.17.18.19. 20.21. 22. 23.24.25. 26.27.28.29.30.31.32.characterization of your basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004, 10:5367?374. Thike AA, Cheok PY, Jara-Lazaro AR, Tan B, Tan P, Tan PH: Triple-negative breast cancer: clinicopathological traits and relationship with basal-like breast cancer. Mod Pathol 2010, 23:123?33. Murray LJ, Abrams TJ, Long KR, Ngai TJ, Olson LM, Hong W, Keast PK, Brassard JA, O’Farrell AM, Cherrington JM, Pryer NK: SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis 2003, 20:757?66. B erle T, Merz M, Komljenovic D, Zwick S, Semmler W: Drug-induced vessel remodeling in bone metastases as assessed by dynamic contrast enhanced magnetic resonance imaging and vessel size imaging: a longitudinal In vivo study. Clin Cancer Res 2010, 16:3215?5. Bello E, Taraboletti G, Colella G, Zucchetti M, Forestieri D, Licandro SA, Berndt A, Richter P, D’Incalci M, Cavalletti E, Giavazzi R, Camboni G, Damia G: The tyrosine kinase inhibitor E-3810 combined with paclitaxel inh.